Diferencia entre revisiones de «Template:Amiodarone adverse effects»
(Created page with "*Bradycardia *Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. *Prolonged QT *Thyrotoxicosis<ref>Rosen's 8th Edition</ref> **...") |
Sin resumen de edición |
||
| Línea 1: | Línea 1: | ||
*Bradycardia | *[[Bradycardia]] | ||
*Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | *Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | ||
*[[Prolonged QT]] | *[[Prolonged QT]] | ||
Revisión del 13:01 5 ene 2016
- Bradycardia
- Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
- Prolonged QT
- Thyrotoxicosis[1]
- Between 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)
- Iodine-induced hyperthyroidism
- It is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Graves’ disease
- Drug-induced destructive thyroiditis
- More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.
- Amiodarone Pulmonary Toxicity
- ↑ Rosen's 8th Edition